jounce.png
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
04 juin 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
06 mars 2019 06h30 HE | Jounce Therapeutics, Inc.
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with...